G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, because that oh-too-familiar routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? To cope, as always, we are looking forward to a few cups of stimulation, although our own routine is slightly modified due to meetings in the STAT world headquarters. Nonetheless, we will maintain our usual output and contact with you. On that note, here are a few tidbits to get you going. Hope you have a swell day and do keep in touch …

The U.K.’s National Health Service could recover up to $700 million from Pfizer (PFE) following a lengthy battle over the patent of its Lyrica painkillerThe Telegraph writes, citing this analysis. Pfizer obtained an additional patent protecting the drug as a pain treatment until July 2017, and argued generics would inevitably be used for the indication and infringe its patent. A court disagreed, but Pfizer is appealing. The NHS, meanwhile, has had to pay the brand price. If the final appeal fails, the NHS should be able to reclaim from Pfizer the money it would have saved by prescribing a generic version.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy